Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + trastuzumab emtansine versus placebo + trastuzumab emtansine in HER2-positive early breast cancer
PACTR202201721209443Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of atezolizumab, trastuzumab emtansine in breast cancer, sponsored by Roche. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
atezolizumabtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202201721209443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201721209443.